Study: NCT03813108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization
Description: Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization
Description: Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine prophylaxis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF135.C10
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: malaria challenge infection, P. falciparum NF54
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: malaria challenge infection, P. falciparum NF54
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization (A/L)
Description: Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization (A/L)
Description: Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes and receive presumptive treatment with artemether/lumefantrine initiated on day 7 after each immunization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.

Intervention type: DRUG
Group type: OTHER
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.

Intervention type: DRUG
Group type: OTHER
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.

Intervention type: DRUG
Group type: OTHER
Intervention: Atovaquone / Proguanil Oral Tablet [Malarone]
Description: All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.